



## **Rexgenero secures Innovate UK Grant**

### **Grant awarded to lead cost effective manufacturing strategy of its lead product REX-001**

**London, UK, 23<sup>rd</sup> January 2018:** Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on Critical Limb Ischemia (CLI), today announces it has secured, with its project consortium partners, £1.4 million in funding for a £1.8 million project from Innovate UK, the UK's innovation agency, to lead an industrial research project of the commercial manufacture of its product REX-001.

The aim of the research project, entitled "Cost-driven process redesign, automation and scale-out for commercial manufacture of REX-001 therapy", is to design a cost-effective manufacturing strategy for Rexgenero's autologous cell-based therapy over a 21-month period. The grant is a consortium between the Cell and Gene Therapy (CGT) Catapult, TrakCel and Fisher Bioservices (part of Thermo Fisher Scientific).

REX-001 is a novel autologous cell therapy that has been shown to stimulate the growth of new blood vessels to restore blood supply to the limb, alleviate symptoms and improve quality of life of patients with CLI.

**Joe Dupere, Rexgenero's CEO,** said "We are pleased to receive this grant from Innovate UK and to work with CGT Catapult, TrakCel and Fisher Bioservices to conduct this important research into cost-effective commercial cell manufacturing. Innovate UK is committed to be a driving force in healthcare innovation and, through CGT Catapult, to establish the UK as the leading gateway for the regenerative medicine field in Europe." Joe added, "The grant will be instrumental to help us develop cost-effective manufacturing for REX-001 at commercial-scale to support launch of the product throughout the UK and Europe from a small number of strategic manufacturing hubs."

**Keith Thompson, CEO, Cell and Gene Therapy Catapult,** said: "We are delighted to be working with Rexgenero, TrakCel and Fisher Bioservices to design a cost-effective manufacturing strategy for Rexgenero's autologous cell-based therapy. The project is a great example of using the end to end capabilities of the Catapult and the cluster of expert firms supporting the growing UK Advanced Therapy ecosystem."

**Ravi Nalliah, CEO, TrakCel,** said: "The commercialisation phase for cell therapies requires multi-layered supply chains involving many patients, individuals and organisations. This is why consortiums and organisations focused on commercializing cell therapies require an advanced software developer for supply chain tracking and orchestration. By adding TrakCel's capabilities to consortia, such as the consortium concentrating on the REX-001 project, this enables a more effective commercialisation strategy for cell therapies to reach patients more effectively."

**Robert Jones, Global Director, Advanced Therapies at Fisher Bioservices** (part of Thermo Fisher Scientific), commented: "We are really excited to participate in this Innovate UK funded project

alongside Rexgenero, CGT Catapult and TrakCel. The output will undoubtedly help drive cost-effective manufacturing of advanced therapies and the creation of a high quality, robust supply chains that will ultimately allow greater access to cell and gene therapies for patients across the UK and beyond.”

-ENDS-

#### Contacts:

Rexgenero  
Joe Dupere, CEO  
T: +44 (0) 203 709 1969  
E: [info@rexgenero.com](mailto:info@rexgenero.com)

Citigate Dewe Rogerson  
Sylvie Berrebi, Shabnam Bashir  
T: +44 (0) 20 7638 9571  
E: [rexgenero@citigatedewerogerson.com](mailto:rexgenero@citigatedewerogerson.com)

#### **About Rexgenero**

Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.

The Company’s lead candidate REX-001 is a highly innovative autologous cell therapy that is being studied in two Phase III clinical trials in patients with Critical Limb Ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective in Phase I/II and Phase II trials, alleviating CLI in the majority of patients, offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.

Rexgenero is a privately-owned company, which draws on an exceptional understanding of the fundamental science of cell therapies developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies.

The Company was founded in 2015 and is headquartered in London (UK) with R&D and manufacturing operations in Seville (Spain).

For more information, please visit [www.rexgenero.com](http://www.rexgenero.com)

#### **About Innovate UK**

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organizations to find and drive the science and technology innovations that will grow the UK economy.

For further information visit [www.innovateuk.gov.uk](http://www.innovateuk.gov.uk)

Rexgenero’s grant can be found here: [Medicines Manufacturing Round 1: Challenge Fund – CRD](#)

#### **About the Cell and Gene Therapy Catapult**

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene

therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK.

For more information please visit [ct.catapult.org.uk](http://ct.catapult.org.uk) or visit [www.gov.uk/innovate-uk](http://www.gov.uk/innovate-uk)

### **About TrakCel**

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel's solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.